What Oncology Pharmacists Need to Know About Targeting BCMA in Early Relapsed/Refractory Myeloma

In this podcast episode, Donald Moore, PharmD, BCPS, BCOP, DPLA, FCCP, FASHP, and Anthony Perissinotti, PharmD, BCOP, discuss the role, efficacy, and safety of agents targeting BCMA in the personalized care of patients with multiple myeloma after disease progression on 1 or 2 previous lines of therapy, including:

• A Brief Overview of BCMA in Multiple Myeloma
• Advances in BCMA-Targeted Agents in Progressing Myeloma
• Selection of BCMA-Directed Therapies for Early Relapse MM
• Operational Challenges Faced by Oncology Pharmacists Regarding the Incorporation of BCMA-Targeted Agents in Practice
• Identifying and Managing Adverse Events Associated With BCMA-Directed Agents

Presenters: 

Donald Moore, PharmD, BCPS, BCOP, DPLA, FCCP, FASHP Clinical Oncology Pharmacy Manager Atrium Health Levine Cancer Institute Charlotte, North Carolina

Anthony Perissinotti, PharmD, BCOP Hematology Clinical Pharmacist Specialist University of Michigan Ann Arbor, Michigan

Link to full program:https://bit.ly/4gCsgXt

Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.